Want to join the conversation?
Deutsche Bank analyst David Begleiter questions $ALB on Fine Chemistry's contributions on the increase in guidance. CEO Luke Kissam says that FCS is not going to perform as well in 2H16 as forecasted in 1H16. The company has got headwinds that it got for SunEdison as well as lower potash pricing and volume.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?